• Evolutionary Perspectives
• 42 min
  1. Antibiotic resistance: a mechanistic overview

  • Dr. Neil Woodford
• 20 min
  2. Mutation

  • Prof. Stephen Gillespie
• 11 min
  3. Fitness in antibiotic resistant bacteria

  • Prof. Stephen Gillespie
• 34 min
  4. Fitness and compensation

  • Dr. Sébastian Gagneux
• 22 min
  5. Antibiotic resistance and the supragenome hypothesis

  • Dr. Bambos Charalambous
• Epidemiology and Clinical Impact
• 37 min
  6. Methicillin resistant S. aureus and other resistances

  • Prof. Mark Enright
• 43 min
  7. Risk factors for antibiotic resistance in Streptococcus pneumoniae

  • Prof. Keith Klugman
• 38 min
  8. Beta-lactamases: clinical impact and epidemiology

  • Prof. Sebastian Amyes
• 49 min
  9. Glycopeptide-resistant enterococci

  • Dr. Neil Woodford
• 33 min
  10. Drug resistant tuberculosis: biology, epidemiology and control

  • Dr. Christopher Dye
• 26 min
  11. Antiretroviral drug resistance

  • Prof. Deenan Pillay
• 49 min
  12. Malaria - changing paradigms

  • Dr. Janet Cox-Singh
• 42 min
  13. Advances in mode of action of antimalarials and resistance mechanisms 1

  • Prof. David Warhurst
• 38 min
  14. Advances in mode of action of antimalarials and resistance mechanisms 2

  • Prof. David Warhurst
• Diagnosis and Surveillance of Resistance
• 29 min
  15. Conventional and automated diagnostic methods

  • Dr. Alan Johnson
• 38 min
  16. National and international surveillance of antibiotic resistance 1

  • Prof. David Livermore
• 50 min
  17. National and international surveillance of antibiotic resistance 2

  • Prof. David Livermore
• Controlling Antibiotic Resistance
• 39 min
  18. Controlling antibiotic resistance in the hospital environment

  • Dr. Ian Eltringham
• 27 min
  19. Controlling antibiotic resistance in the community

  • Dr. Peter Wilson
• 51 min
  20. Public policy to reduce antibiotic resistance

  • Dr. Niels Frimodt-Møller
• The Antibiotic Resistance Future
• 26 min
  21. Overcoming resistance through novel drug targets

  • Prof. Anthony Coates
• 37 min
  22. Medicinal chemistry strategies in combating antibiotic resistance

  • Dr. Geoffrey Coxon
• 36 min
  23. Teixobactin kills pathogens without detectable resistance

  • Prof. Kim Lewis
• Archived Lectures *These may not cover the latest advances in the field
• 48 min
  24. Molecular diagnosis of antibiotic resistance

  • Dr. Tim McHugh
• 36 min
  25. Introduction to malaria

  • Prof. David Warhurst

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Drug resistance mechanisms
3. Chloroquine-resistance in falciparum malaria
4. Chloroquine-resistance caused raised fatality
5. Resistance mechanisms
6. PfCRT (coded on chromosome 7)
7. PfCRT based on structure of E. coli 1PW5
8. The ancestor of PfCRT may be a thiol carrier CLT
9. Activity of D-AQ in CQ-R
10. AQ selected the SVMNT CQ-resistance variant
11. Can CQ become useful once more?
12. Resistance to artemisinin
13. Mutations in Pgh-1
14. PgH-1
15. Modeled PgH-1 transporter
16. Mouse PgH-1 transporter model
17. Mutated protein pumps more HF into the DV
18. Resistance mechanisms summary
19. Rationale for ACT
20. UBP-1 changes associated with drug-resistance
21. Piperaquine and dihydroartemisinin combination
22. Life cycle stage as drug target - summary (1)
23. Life cycle stage as drug target - summary (2)
24. Controlling the spread of resistance
25. Approach to urgent treatment for severe malaria
26. Intermittent preventive treatment: IPT

Topics Covered

• Drug resistance mechanisms
• Chloroquine-resistance in falciparum malaria
• PfCRT protein -Resistance to artemisinin
• PgH-1
• Rationale for Artemisinin combination therapy
• Controlling the spread of resistance
• Approach to urgent treatment for severe malaria
• Intermittent preventive treatment

Links

Series:

• Antibiotic Resistance

Categories:

• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on November 6, 2013

Financial Disclosures

• Prof. David Warhurst has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.